Display Settings:

Format

Send to:

Choose Destination
Curr Opin Investig Drugs. 2003 Apr;4(4):466-71.

SomatoKine. Insmed.

Author information

  • Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com

Abstract

SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. By July 2002, the FDA had granted SomatoKine Orphan Drug status for the treatment of GHIS. Also at this time, a phase II trial in children suffering from GHIS was initiated. In September 2002, Insmed expected to initiate a further clinical trial in GHIS in early 2003, and planned to continue phase II development in type 1 and type 2 diabetes.

PMID:
12808889
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk